< GPCR News < GPCRs in Oncology and Immunology Role and recent progress of P2Y12 receptor in cancer development P2Y12R is involved in cancer development and metastasis, while P2Y12R inhibitors are effective in inhibiting

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Developing During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods

His thesis work led to the development and application of light energy transfer methodology to study His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development

At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies

via mesenchymal Gαq/11-mediated TGFβ2 activation Published date April 27, 2023 Abstract " Alveolar development To understand the role of mesenchymal Gαq/11 in lung development, we generated constitutive (Pdgfrb-Cre Mice with constitutive Gαq/11 gene deletion exhibited abnormal alveolar development, with suppressed Tags Alveologenesis , Cyclical mechanical stretch , GPCR , Gαq/11 , Lung development , TGFβ .

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop We are also currently developing the translational component of our research to capitalize on the druggability We hope our research will aid in the development of new therapeutic interventions for the alleviation

I have 10 years of experience in the development and management of R&D projects and teams in the field I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila moved to King's College London, where my interest and passion for kinases in brain health and disease developed I have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon

One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

review highlights the specific molecular actions and signaling pathways of olfactory receptors in the development Protein-coupled receptors , Olfactory receptors , Therapeutic targeting , Tumor cell proliferation , Tumor development

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

Because of this, we developed and validated a sensitive, specific, semi-quantitative method for detecting We believe our data should stimulate studies of receptor function and contribute to drug development.

She developed expertise over the past two decades studying structure/function relationships of GPCRs Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Driven by a passion for advancing drug development, John is committed to leveraging his expertise to Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal

His research interest lies in understanding the molecular basis for human tumor development and how to Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor His research aims to translate these novel agents to testing in clinical trials with the hope to develop the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development

and reprograms fungal cells for nematode hunting Published date June 14, 2024 Abstract "Initiation of development A. flagrans develops adhesive traps and recognizes its prey, Caenorhabditis elegans, through nematode-specific